ALAndrew S. Lee

Andrew S. Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew S. Lee has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Skeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy

    by Yu Tian, Yutong Liu, Yuhao Tong, Kristin Huntoon, Liqun Yang, Junfeng Shi, Yifan Ma, Shiyan Dong, Seong Dong Jeong, Andreanne Poppy Estania, et al.

    Duchenne muscular dystrophy (DMD) is a severe, progressive muscle-wasting disorder caused by mutations in the DMD gene, which encodes dystrophin. Although gene therapy using viral vectors has shown promise for the treatment of DMD, the clinical application of viral gene therapies is limited by vector toxicity, immunogenicity and the inability to package full-length dystrophin. Recent advances in messenger RNA (mRNA) technology offer a non-integrating, transient approach to restoring protein expression. Here we report the systemic delivery of skeletal-muscle-targeted full-length DMD mRNA in a murine model of DMD using allogenically engineered targeting extracellular vesicles (DMD t-EVs). This approach restores the endogenous translation of wild-type dystrophin and substantially improves muscle function. We further demonstrate the safety and biocompatibility of DMD t-EVs in non-human primates, supporting their translational potential. These findings highlight the promise of mRNA-loaded extracellular vesicles as a therapeutic platform for treating genetic disorders involving large, difficult-to-package genes.


  • Top Cited Papers

    Engineering challenges and translational opportunities in emerging gene delivery platforms

    by Yifan Ma, Shiyan Dong, Annette Wu, Seong Dong Jeong, Andrew S. Lee, Wen Jiang, Betty Y. S. Kim

    The clinical success of gene therapy depends critically on the development of delivery platforms capable of achieving precise, efficient and tissue-specific delivery of genetic payloads in vivo. A diverse array of carriers, including viral, non-viral, synthetic and natural vectors, have been explored to address this challenge. Among them, adeno-associated viruses, lipid nanoparticles and extracellular vesicles have emerged as leading candidates, each offering distinct advantages and translational hurdles. Here we provide a comparative analysis of these delivery modalities, highlighting their respective design principles, targeting capabilities, immunogenicity profiles and clinical progress. We survey preclinical and clinically adopted delivery strategies and explore how the three delivery platforms can be tailored for gene therapeutics in different diseases. Finally, we discuss emerging strategies to overcome current limitations and outline future directions for the rational design of next-generation gene delivery platforms that combine safety, scalability and functional precision.


  • Engineered mucus-tethering bispecific nanobodies enhance mucosal immunity against respiratory pathogens

    by Liming Zhao, Kyle L. O’DOnnell, Megha Dubey, Yuting Wang, Nathan R. Martinez, Yunxiao Zhang, Holly M. Steininger, Chao Ma, Vamsee Mallajosyula, Lorene L. Y. Lee, et al.

    Despite advances in vaccine and antiviral drug development, the prevention of respiratory viral infection and transmission remains a substantial challenge worldwide. One obvious limitation of these approaches is that they do not provide robust protection at the initial site of infection, which is the respiratory mucosa. Currently, strategies to enhance mucosal immunity against respiratory pathogens remain lacking. Here we engineered mucus-tethering bispecific nanobodies designed to provide the simultaneous neutralization of viruses by binding to their surface proteins and the entrapment of viruses within the mucus by securing them to mucin. Compared with conventional non-mucus-tethering nanobodies, these mucus-tethering bispecific nanobodies demonstrated increased retention in the respiratory tract, provided enhanced protection against influenza viral infection in mice and reduced SARS-CoV-2 transmission in hamsters. Together, our findings represent a promising strategy for enhancing mucosal defences against respiratory viruses by blocking viral entry and limiting onward transmission.


  • Open Access

    Efficient Scaling up EV‐AAVs Production via Cellular Nanoporation for Familial Hypercholesterolaemia Therapy

    by Yuting Yan, Yi You, Shuhong Ma, Hui Yi, Guangduo Chen, Jie Ni, Changyan Chen, Wenyu Ke, Lingying Li, Rui Bai, et al.

    Adeno‐associated virus (AAV)–mediated gene therapies face critical clinical limitations, including immune‐mediated neutralization by pre‐existing antibodies and dose‐dependent hepatotoxicity. Extracellular vesicle‐encapsulated AAVs (EV‐AAVs) offer a promising solution by shielding AAVs from antibody recognition, yet existing production methods remain inefficient and impractical for clinical application. Here, we developed a cellular nanoporation (CNP) platform that enables scalable, high‐yield generation of EV‐AAVs, achieving an approximately 11‐fold increase in production efficiency compared with conventional methods. In LDLR‐deficient murine models with pre‐existing neutralizing antibodies (1:200), EV‐AAV‐LDLR at half the standard AAV dose robustly restored hepatic LDL receptor expression and attenuated atherosclerosis progression. Notably, EV‐AAV exhibited superior immune evasion capabilities, maintaining 2.3‐fold higher hepatic transduction efficiency than conventional AAV upon secondary dosing due to antibody shielding. Importantly, EV‐AAV therapy markedly reduced hepatotoxicity, with serum AST/ALT levels comparable to saline‐treated controls, thereby overcoming a critical safety barrier of high‐dose AAV treatment. These results demonstrate CNP as a clinically translatable platform for scalable EV‐AAV manufacturing, enabling effective multi‐dose regimens while overcoming key immunological and toxicity barriers in liver‐directed gene therapy for familial hypercholesterolaemia.


  • Open Access

    Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer

    by Chi-Ling Chiang, Yifan Ma, Ya-Chin Hou, Junjie Pan, Sin-Yu Chen, Ming-Hsien Chien, Zhi-Xuan Zhang, Wei-Hsiang Hsu, Xinyu Wang, Jingjing Zhang, et al.

    Pancreatic ductal adenocarcinoma (PDAC) tumours carry multiple gene mutations and respond poorly to treatments. There is currently an unmet need for drug carriers that can deliver multiple gene cargoes to target high solid tumour burden like PDAC. Here, we report a dual targeted extracellular vesicle (dtEV) carrying high loads of therapeutic RNA that effectively suppresses large PDAC tumours in mice. The EV surface contains a CD64 protein that has a tissue targeting peptide and a humanized monoclonal antibody. Cells sequentially transfected with plasmid DNAs encoding for the RNA and protein of interest by Transwell®-based asymmetric cell electroporation release abundant targeted EVs with high RNA loading. Together with a low dose chemotherapy drug, Gemcitabine, dtEVs suppress large orthotopic PANC-1 and patient derived xenograft tumours and metastasis in mice and extended animal survival. Our work presents a clinically accessible and scalable way to produce abundant EVs for delivering multiple gene cargoes to large solid tumours.


  • Open Access

    Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer

    by Shiyan Dong, Xuan Liu, Ye Bi, Yifan Wang, Abin Antony, DaeYong Lee, Kristin Huntoon, Seongdong Jeong, Yifan Ma, Xuefeng Li, et al.

    The recent success of mRNA therapeutics against pathogenic infections has increased interest in their use for other human diseases including cancer. However, the precise delivery of the genetic cargo to cells and tissues of interest remains challenging. Here, we show an adaptive strategy that enables the docking of different targeting ligands onto the surface of mRNA-loaded small extracellular vesicles (sEVs). This is achieved by using a microfluidic electroporation approach in which a combination of nano- and milli-second pulses produces large amounts of IFN-γ mRNA-loaded sEVs with CD64 overexpressed on their surface. The CD64 molecule serves as an adaptor to dock targeting ligands, such as anti-CD71 and anti-programmed cell death-ligand 1 (PD-L1) antibodies. The resulting immunogenic sEVs (imsEV) preferentially target glioblastoma cells and generate potent antitumour activities in vivo, including against tumours intrinsically resistant to immunotherapy. Together, these results provide an adaptive approach to engineering mRNA-loaded sEVs with targeting functionality and pave the way for their adoption in cancer immunotherapy applications.


  • Top Cited Papers

    Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy

    by Yi You, Yu Tian, Zhaogang Yang, Junfeng Shi, Kwang Joo Kwak, Yuhao Tong, Andreanne Poppy Estania, Jianhong Cao, Wei-Hsiang Hsu, Yutong Liu, et al.

    The success of messenger RNA therapeutics largely depends on the availability of delivery systems that enable the safe, effective and stable translation of genetic material into functional proteins. Here we show that extracellular vesicles (EVs) produced via cellular nanoporation from human dermal fibroblasts, and encapsulating mRNA encoding for extracellular-matrix α1 type-I collagen (COL1A1) induced the formation of collagen-protein grafts and reduced wrinkle formation in the collagen-depleted dermal tissue of mice with photoaged skin. We also show that the intradermal delivery of the mRNA-loaded EVs via a microneedle array led to the prolonged and more uniform synthesis and replacement of collagen in the dermis of the animals. The intradermal delivery of EV-based COL1A1 mRNA may make for an effective protein-replacement therapy for the treatment of photoaged skin.